Clinical Trials Approved for Italy

January 19, 2017

 

Alpha Tau Medical has received IRB approval from IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), in Italy for clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in skin cancer.

The company is also in the process of finalizing additional protocols for clinical trials in Colorectal and Prostate cancers. Initial trials are due to start within the next few months.

Alpha DaRT technology enables the possibility of providing brachytherapy treatment based on alpha emitters, and has several advantages:

  1. Highly Potent and Ultra conformal

  2. Effective regardless of tumor oxygen level

  3. Short half-life – quick clinical results

  4. Negligible gamma radiation, no special shielding equipment is needed

  5. Disposable product – not capital equipment is needed

To keep up to date on our progress in the clinical trials, please follow us on LinkedIn https://www.linkedin.com/company/10538741 , Twitter https://twitter.com/AlphaTauMedical or subscribe to our newsletter.

 

 

 

Share on Facebook
Share on Twitter
Please reload

Please reload

Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

1/5
Please reload

Archive
Please reload

Categories
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.